Investors should always be on the lookout for insights that could give them an edge in the stock market, and one potential source of such information is insider buying activity. When company insiders, such as executives or board members, buy shares of a company’s stock, it can be seen as a vote of confidence in the company’s prospects. Publicly available insider buying information can provide valuable clues about which stocks may be worth considering for investment.
Here are three stocks recently purchased by C-level insiders –
B. Riley Financial, Inc. – SYM: RILY
Recent Price: $28.79
Insider Action: 4 insiders buy $2.4 mil in shares
Description: B. Riley Financial, Inc., through its subsidiaries, provides financial services to corporate, institutional, and high net worth clients in North America, Australia, and Europe. The company operates through six segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer.
===
Atlas Energy Solutions Inc. – SYM: AESI
Recent Price: $17.15
Insider Action: 3 insiders buy $5.3 mil in shares
Description: Atlas Energy Solutions Inc. provides proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico. The company was founded in 2017 and is based in Austin, Texas.
===
Praxis Precision Medicines, Inc. – SYM: PRAX
Recent Price: $1.01
Insider Action: 3 insiders buy $109K in shares
Description: Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson’s disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
